Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ibnsina PharmaCAI:ISPH +0.77%86 Return-on-Tangible-Equity is 39.36% as of Mar. 2026, which is 25% above its 10-year median of 31.38. GuruFocus rates CAI:ISPH with a GF Score™ of 86/100 and a GF Value™ of E£10.58 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 112 Medical Distribution companies, Ibnsina Pharma ranks better than 81.25% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Ibnsina Pharma's annualized net income for the quarter that ended in Mar. 2026 was E£1,024 Mil. Ibnsina Pharma's average shareholder tangible equity for the quarter that ended in Mar. 2026 was E£2,601 Mil. Therefore, Ibnsina Pharma's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 39.36%.
The historical rank and industry rank for Ibnsina Pharma's Return-on-Tangible-Equity or its related term are showing as below:
CAI:ISPH'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 12.87 Med: 31.38 Max: 44.42
Current: 44.31
During the past 10 years, Ibnsina Pharma's highest Return-on-Tangible-Equity was 44.42%. The lowest was 12.87%. And the median was 31.38%.
CAI:ISPH's Return-on-Tangible-Equity is ranked better than 81.25% of 112
companies
in the Medical Distribution industry
Industry Median: 8.755
vs CAI:ISPH: 44.31
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Ibnsina Pharma Return-on-Tangible-Equity Related Terms
Ibnsina Pharma Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Ibnsina Pharma's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAI:ISPH vs MCK, CAH, COR: Return-on-Tangible-Equity Comparison
For the Medical Distribution subindustry, Ibnsina Pharma's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ibnsina Pharma Return-on-Tangible-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ibnsina Pharma's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Ibnsina Pharma's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 39.36% mean?
Ibnsina Pharma (CAI:ISPH) has a Return-on-Tangible-Equity of 39.36% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Ibnsina Pharma and its competitors. This is 25% above median its historical median of 31.38. Over the past decade, Ibnsina Pharma's Return-on-Tangible-Equity has ranged from 12.87 to 44.42. According to the industry distribution chart, Ibnsina Pharma ranks #21 out of 112 companies in the Medical Distribution industry, placing it in the top 18.7%.
Is Ibnsina Pharma's Return-on-Tangible-Equity too high?
Ibnsina Pharma's current Return-on-Tangible-Equity of 39.36% is 25% above median its 10-year median of 31.38. Over the past 10 years, this metric has ranged from a low of 12.87 to a high of 44.42. The Medical Distribution industry median Return-on-Tangible-Equity is 8.76. Ibnsina Pharma's value of 39.36% is 349.6% above this industry median. Based on the distribution chart, Ibnsina Pharma ranks #21 out of 112 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Ibnsina Pharma has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ibnsina Pharma's Return-on-Tangible-Equity compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Ibnsina Pharma ranks #21 out of 112 companies for Return-on-Tangible-Equity. This places Ibnsina Pharma in the top 19% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 8.76. Ibnsina Pharma's value of 39.36% is 349.6% above this benchmark. Historically, Ibnsina Pharma's own Return-on-Tangible-Equity has ranged from 12.87 to 44.42 over the past decade. While the company's 10-year median is 31.38 vs. the industry median of 8.76, Ibnsina Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Distribution company?
The median Return-on-Tangible-Equity among Medical Distribution companies is 8.76, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ibnsina Pharma's current Return-on-Tangible-Equity of 39.36% is 349.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Ibnsina Pharma and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Equity is 8.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ibnsina Pharma's current Return-on-Tangible-Equity is 39.36%, which is 25% above median its own 10-year median of 31.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ibnsina Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ibnsina Pharma (CAI:ISPH) is currently considered Modestly Overvalued. The stock's GF Value™ is E£10.58, compared to a current price of E£11.73 — trading 10.9% above its estimated fair value. The current Return-on-Tangible-Equity is 39.36%, which is 25% above median its 10-year median of 31.38 and 349.6% above the Medical Distribution industry median of 8.76. Ibnsina Pharma's overall GF Score™ is 86/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Ibnsina Pharma (CAI:ISPH), the current Return-on-Tangible-Equity is 39.36% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ibnsina Pharma (CAI:ISPH) Overvalued in 2026?
Based on GuruFocus' analysis, Ibnsina Pharma stock appears to be overvalued.
The current stock price of E£11.73 is trading 10.9% above its estimated GF Value™ of E£10.58.
GuruFocus considers Ibnsina Pharma to be Modestly Overvalued.
Key valuation signals for CAI:ISPH:
Return-on-Tangible-Equity: 39.36% (25% above median its 10-year median of 31.38)
GF Value™: E£10.58 vs. price of E£11.73 (10.9% above fair value)
Industry Position: 349.6% above the Medical Distribution median (#21 of 112)
No single metric tells the full story. See the CAI:ISPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ibnsina Pharma is an Egypt-based pharmaceutical distribution company. It is engaged in purchasing and selling in wholesale and distribution of pharmaceutical, semi- pharmaceutical, and cosmetic products. It distributes a portfolio of pharmaceutical products from local and multinational pharmaceutical companies to retail pharmacies, wholesalers, hospitals, and public health institutions. In addition, the company also offers services including warehousing and logistics, marketing solutions, importation, packaging, market research, and analysis.
86GF Score
Get the complete analysis for CAI:ISPH
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:ISPH has been successfully added to your 
